Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tominersen - Ionis Pharmaceuticals

Drug Profile

Tominersen - Ionis Pharmaceuticals

Alternative Names: HTT ASO; IONIS-HTTRx; ISIS-443139; ISIS-HTT Rx; RG 6042; RO-7234292

Latest Information Update: 13 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals; Roche
  • Class Antisense oligonucleotides; Neuroprotectants
  • Mechanism of Action Huntingtin protein expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Huntington's disease

Most Recent Events

  • 09 May 2024 Roche plans to file regulatory application for Huntington’s disease, in or after 2027 (Roche pipeline, May 2024)
  • 19 Jan 2023 Roche initiates phase II GENERATION HD2 for Huntington's-disease in USA (NCT05686551)
  • 09 Nov 2022 Roche plans to begin enrolment in phase II GENERATION HD2 trial for Huntington's disease in early 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top